Upper Airway's Pressure Drop Analyses After Mandibular Advancement and Maxillary Expansion
NCT ID: NCT04190953
Last Updated: 2025-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
90 participants
INTERVENTIONAL
2020-02-18
2026-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
However a change in shape, even with the same volume, can affect the pressure and airflow. In this sense, the pressure drop analysis will allow an answer to those questions
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Oral Appliance Therapy on Masseter Muscle Activity in Obstructive Sleep Apnea
NCT02011425
Study the Effect of Upper Expansion Appliances on Lower Jaw Forward Projection/Growth
NCT03286569
Efficacy of Mini-implant Assisted Maxillary Expansion in Adolescents and Adults
NCT06449014
Comparing Two Mandibular Positioning Techniques for Dental Sleep Appliances
NCT05553860
Pharyngeal Airway Dimensions With Twinblock Versus Myobrace Appliances in Developing Skeletal Class II Patients
NCT05610150
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. There is an increase in upper airway volume and minimal cross-sectional area after maxillary expansion and mandible repositioning in class II malocclusion children using Hyrax and Twin-block.
2. There is a larger increase in the airway dimensions and a larger decrease in the air resistance (in the pressure drop analysis) in the group started with the mandibular advancement device.
3. There is a change in the shape of the upper airway after maxillary expansion and mandible repositioning in class II malocclusion children using Hyrax and Twin-block.
4. There is a correlation between the increase in airway volume, the change in shape and an increase in airflow using in vitro simulated airway experiments.
5. There is an increase in respiratory capability when evaluated with in-home portable PSG (after maxillary expansion and mandible repositioning).
6. There is a positive correlation to the in-home portable Polysomnography (PSG) with the results acquired by volume, shape, airflow and pressure drop.
Methods
The inclusion criteria are children between the ages 8-14 years old (8-12 years old girls and 9-14 years old boys), presenting skeletal class II division 1 malocclusion with maxillary constriction. The study design is a randomized crossover controlled trial. 90 patients will be randomly allocated into three groups:
Group 1: 30 patients will immediately undergo to Hyrax/Twin-block treatment, the patients will have the maxillary expansion treatment (Part I) before the mandibular repositioning (Part II).
Group 2: 30 patients will immediately undergo Twin-block/Hyrax treatment, the patients will have the mandibular repositioning treatment (Part I) done before the maxillary expansion (Part II).
Group 3: 30 patients will wait 1,5 years to begin the treatment. Since all patients are in the pre-pubertal/pubertal phase, this 1,5-year delay treatment for group 3 will neither compromise future treatment decisions nor results.
Aim 1: To determine the changes in the upper airway volume, minimal cross-sectional area, the lumen (geometry/shape), airflow, air velocity and pressure after maxillary expansion and mandibular advancement in children. Those changes will be compared between tested and control groups.
The upper airway will be assessed through Cone Bean Computed Tomography (CBCT)s exams, to analyze the volume changes before and after the use of the Twin-block and Hyrax, using the Avizo software (Thermo Fisher Scientific, Berlin, Germany). The pressure drop will be assessed using the CBCTs to generate a Stereolithography (STL) file to print upper airway models to analyze airflow, air velocity and pressure characteristics before and after the orthodontic treatment in children. Those results will be correlated. Also, the correlation will be done between tested and control groups. Pressure drop related measurements and airway volume will be assessed at T0 - before treatment, T1- after part II in the treated groups and T0 and after 1.5 years in the control group.
Aim 2: To determine changes in the in-home portable PSG results before and after maxillary expansion and mandibular repositioning and to correlate them to the results collected by the upper airway model's evaluations using pressure drop to determine airflow, velocity, pressure, and upper airway dimensions.
Patients will undergo an in-home PSG test at the beginning of treatment (T0). Groups 1 and 2 will have in-home PSG tested again after Part I and II. Group 3 will be tested at T0 and after one year. Through the CBCTs the volume and minimal cross-sectional area, and related measurements to pressure drop test will be assessed and correlated to the results from the in-home portable PSG. Likewise, the changes will be compared between tested and control groups.
Aim 3: To describe dental and skeletal changes in the class II patients undertaken the Twin-block/Hyrax treatment.
Linear measurements using craniofacial landmarks will be assessed through CBCT exams to determine the amount of skeletal and dental changes obtained. All patients will have those measurements assessed at T0. Groups 1 and 2 will also have linear measurements assessed after Part II. Group 3 will have linear measurements reassessed after 1.5 years from the first CBCT.
General information The CBCTs will be analyzed using Avizo software (Thermo Fisher Scientific, Berlin, Germany) for volume and linear measurement. Printed upper airway for the Pressure drop test for airflow/pressure drop/air velocity simulations will be made at all time-points.
All patients will have breathing capacity tested through in-home portable PSG, one week before the beginning of treatment, after parts I and II in groups 1 and 2 and at T0 and 1.5 years after the first test for group 3.
A subjective evaluation of the airway using the questionnaire Nasal Obstruction Symptom Evaluation (NOSE) Instrument, with 18 questions, will be given to patients. A Paediatric Sleep Questionnaire (PSQ) will also be used. An objective airway evaluation will be made using Peak Nasal Inspiratory Flow (PNIF) and Peak Oral Inspiratory Flow (POIF) tests, which are measured with the In-Check medical device at the same time-points as in-home PSG tests. Those tests and questionnaires will be used to correlate all the findings and clinical significance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Twin Block then Hyrax
Patients will undergo mandibular advancement prior to maxillary expansion using Twin block prior to Hyrax
Twin block then Hyrax
Patients will undergo mandibular advancement prior to maxillary expansion
Hyrax then Twin block
Patients will undergo maxillary expansion prior to mandibular advancement using Hyrax prior to Twin block
Hyrax then Twin block
Patients will undergo maxillary expansion prior to mandibular advancement
Control
Patients will wait 1,5 years before the start of treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Twin block then Hyrax
Patients will undergo mandibular advancement prior to maxillary expansion
Hyrax then Twin block
Patients will undergo maxillary expansion prior to mandibular advancement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
8 Years
14 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Silvia G Capenakas, MSc
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alberta
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00095427
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.